Novo Nordisk's Tresiba Receives Health Canada Approval for Type 1 Diabetes in patients Aged ≥2 years
Shots:
- Novo Nordisk’s Tresiba has received an approval for indication expansion by Health Canada for the treatment of pediatric patients (>2 years of age) with Type 1 diabetes
- The expanded indication follows its last approval in Canada on Aug 2017 for the treatment of adults with Type 1 and Type 2 diabetes
- Tresiba (insulin degludec injection) is a once-daily- ultra-long-acting basal insulin and is available as FlexTouch prefilled- disposable pen for injecting insulin
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
